Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company’s pipeline is comprised of therapeutic antibodies, antibody-drug conjugates, immune system modulators and other protein-based therapeutics that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications. This has created a leading pipeline in immunotherapy and targeted cancer therapies with six company-led clinical trials across five product candidates, including a registration study in triple negative breast cancer and five Phase 1 and Phase 2 clinical trials in a range of difficult-to-treat indications, and a robust preclinical engine.
Many of our clinical programs seek to leverage the power of the immune system’s response by combining therapeutic approaches to maximize their potential. Key to this strategy is our ability to understand our own asset base while also identifying promising external technologies that will complement it. In 2005, Celldex was spun out of the New Jersey based biopharmaceutical company Medarex (acquired by the Bristol-Myers Squibb Company) and, in connection with this transaction, Celldex retains the rights to obtain exclusive commercial licenses to proprietary monoclonal antibodies raised against certain antigens utilizing the Medarex UltiMAb technology platform. Since its inception, Celldex has also acquired five companies, folding in five assets, and in-licensed/purchased an additional two assets. With the potential for positive results in ongoing late-stage programs, the next stage in Celldex’s development is to become a fully integrated commercial entity.